Navigation Links
Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
Date:9/3/2008

Martin Cearnal appointed Senior Vice President, Commercial Development

NASHVILLE, Tenn., Sept. 3 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. has appointed industry veteran Martin E. Cearnal as Senior Vice President, Commercial Development. In this newly created position Mr. Cearnal will be directly involved with Cumberland's commercial strategy and business development initiatives.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080903/CLW115 )

Mr. Cearnal brings extensive pharmaceutical experience to his new role. During his 40-year healthcare career, he has been involved with the launches of noteworthy pharmaceutical products including Lipitor(R), Actos(R), Intron-A(R), Straterra(R), Botox(R) and Humira(R). He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education before it was sold to Thomson Healthcare in 2000. He continued his affiliation with the company, serving as President of Thomson Physicians World and Executive Vice President of Thomson Medical Education. Mr. Cearnal began his career at Revlon Healthcare, working in a variety of domestic and international marketing positions and eventually serving as the company's Vice President of Marketing for International Operations. He has been a member of Cumberland's board of directors since 2004.

"We are delighted to have Marty join Cumberland's management team in this important new role," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. "His broad knowledge of the pharmaceutical industry and considerable expertise will be a great asset to our company."

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets branded, prescription products for targeted physician segments, including hospital acute care and gastroenterology. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information, please visit the Cumberland Pharmaceuticals web site at http://www.cumberlandpharma.com.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):